{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:58:15Z","timestamp":1792486695187,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Programmed death-1 (PD-1) and its ligand PD-L1 inhibitors have become pivotal agents in cancer immunotherapy, demonstrating significant efficacy across multiple malignancies. However, beyond regulating T cell activation, the PD-1\/PD-L1 axis also exerts complex and critical effects on bone metabolism. Notably, both clinical observations and mechanistic studies have revealed a paradox: on one hand, PD-1\/PD-L1 blockade appears to confer bone-protective benefits; on the other hand, it has been associated with bone-related adverse events (AEs) in up to 69% of patients, including pathological fractures and vertebral compression fractures. This review comprehensively explores the bidirectional regulatory effects of the PD-1\/PD-L1 pathway on bone metabolism and investigates the underlying mechanisms contributing to these contradictory findings. The discrepancies may be attributed to a combination of clinical variables, microenvironmental conditions, cell-specific responses, and intricate interactions among multiple signaling pathways, including the Wnt\/\u03b2-Catenin pathway and the PD-L1\u2013PKM2 axis. We further examine the pathophysiological basis of osteoporosis and fragility fractures occurring during PD-1\/PD-L1 inhibitor therapy, and argue for their recognition as a subclass of immune-related adverse events (irAEs). Finally, we propose a framework for bone health surveillance and stratified prevention strategies aimed at preserving antitumor efficacy while improving skeletal health and quality of life\u2014offering novel insights into osteoporosis prevention and management in the context of immune checkpoint inhibition.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1630751","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:25:54Z","timestamp":1753421154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The regulatory effects of PD-1\/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2510","article-title":"The effects and safety of PD-1\/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44582","article-title":"Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: A promising breakthrough in cancer therapeutics","volume":"15","author":"Abaza","year":"2023","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773946","article-title":"The programmed death-1 pathway counter-regulates inflammation-induced osteoclast activity in clinical and experimental settings","volume":"13","author":"Greisen","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008669","article-title":"Favorable impact of PD1\/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation","volume":"12","author":"Gassner","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133334","article-title":"PD-1 blockade inhibits osteoclast formation and murine bone cancer pain","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41368-022-00168-2","article-title":"Blockade of PD-L1\/PD-1 signaling promotes osteo-\/odontogenic differentiation through Ras activation","volume":"14","author":"Jeon","year":"2022","journal-title":"Int J Oral Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100459","article-title":"Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis","volume":"37","author":"Pantano","year":"2022","journal-title":"J Bone Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/jbmr\/zjaf009","article-title":"Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning-assisted opportunistic quantitative computed tomography","volume":"40","author":"Matheson","year":"2025","journal-title":"J Bone Miner Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.3390\/cells11193152","article-title":"Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts Differentiated from hADMSCs via the PD-1\/PD-L1 Axis","volume":"11","author":"Lee","year":"2022","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.705","article-title":"OP0106&x2005;SOLUBLE PD-1 PROMOTES LOCAL IL-17A PRODUCTION IN THE INFLAMED MICROENVIRONMENT IN spA","volume":"81","author":"Rasmussen","year":"2022","journal-title":"Ann OF THE RHEUMATIC Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2653","article-title":"Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis","volume":"18","author":"Maeda","year":"2012","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2022.11.009","article-title":"Fibroblast programmed cell death ligand 1 promotes osteoclastogenesis in odontogenic keratocysts","volume":"193","author":"Zhu","year":"2022","journal-title":"Am J Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33592","article-title":"Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis","volume":"149","author":"Filippini","year":"2021","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14412\/1996-7012-2022-5-46-52","article-title":"The debut of inflammatory musculoskeletal pathology in patients receiving anticancer therapy with PD-1\/PD-L1 pathway inhibitors","volume":"16","author":"Koltakova","year":"2022","journal-title":"Sovremennaya Revmatologiya=Modern Rheumatol J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009309","article-title":"Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors","volume":"12","author":"Elsayed","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.32948\/ajo.2022.12.29","article-title":"Adverse effects of the cancer therapy on osteoclast-mediated bone loss in patients with cancers: a challenge","volume":"3","author":"Tran","year":"2022","journal-title":"Asia-Pacific J Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13866","article-title":"The skeletal impact of cancer therapies","volume":"85","author":"Bedatsova","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.29245\/2578-3009\/2018\/5.1162","article-title":"Expression, functions, and treatment target of PD-L1 (B7-H1) in multiple myeloma","volume":"2","author":"Tamura","year":"2018","journal-title":"J\u00a0Immunol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06690-1","article-title":"Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event","volume":"34","author":"Ye","year":"2023","journal-title":"Osteoporos Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf055","article-title":"PD-1 blockade regulates skeletal remodeling in a sex- and age-dependent manner","volume":"40","author":"Joseph","year":"2025","journal-title":"J\u00a0Bone Miner Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0218","article-title":"DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer","volume":"10","author":"Shi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/stmcls\/sxac037","article-title":"PD-1 suppresses the osteogenic and odontogenic differentiation of stem cells from dental apical papilla via targeting SHP2\/NF-\u03baB axis","volume":"40","author":"Li","year":"2022","journal-title":"Stem Cells"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29654","article-title":"Loss of p62 impairs bone turnover and inhibits PTH-induced osteogenesis","volume":"235","author":"Agas","year":"2020","journal-title":"J Cell Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04301-w","article-title":"The role of PKM2-mediated metabolic reprogramming in the osteogenic differentiation of BMSCs under diabetic periodontitis conditions","volume":"16","author":"Zhu","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/JOE-18-0153","article-title":"Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice","volume":"238","author":"Funck\u2013Brentano","year":"2018","journal-title":"J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0799","article-title":"mDKN-01, a novel anti-DKK1 mAb, enhances innate immune responses in the tumor microenvironment","volume":"19","author":"Haas","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191115","article-title":"\u03b2-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion","volume":"217","author":"Du","year":"2020","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000398","article-title":"Increase in\u00a0major osteoporotic fractures after therapy with immune checkpoint inhibitors","volume":"3","author":"Ye","year":"2024","journal-title":"BMJ\u00a0Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1332303","article-title":"Bone mineral density\u00a0as\u00a0an individual prognostic biomarker in NSCLC patients treated with immune\u00a0checkpoint inhibitors","volume":"15","author":"Lou","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0369-x","article-title":"Cancer treatment and bone health","volume":"102","author":"Handforth","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133828","article-title":"Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of Malignant tumors, including pharmacological mechanism and clinical trials","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.961941","article-title":"How zoledronic acid improves osteoporosis by acting on osteoclasts","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107858","article-title":"Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases","volume":"193","author":"Asano","year":"2024","journal-title":"Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12331","article-title":"Zoledronic acid causes \u03b3\u03b4 T cells to target monocytes and down-modulate\u00a0inflammatory homing","volume":"143","author":"Fowler","year":"2014","journal-title":"Immunology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231157194","article-title":"Immune checkpoint inhibitors: friend or foe for osteoporosis","volume":"14","author":"Tang","year":"2023","journal-title":"Ther\u00a0Adv\u00a0Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619209","article-title":"Wnt inhibition sensitizes PD-L1 blockade therapy by overcoming bone marrow-derived myofibroblasts-mediated immune resistance in tumors","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:25:54Z","timestamp":1753421154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1630751"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1630751","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1630751"}}